Indian Journal of Dermatology
  Publication of IADVL, WB
  Official organ of AADV
Indexed with Science Citation Index (E) , Web of Science and PubMed
 
Users online: 476  
Home About  Editorial Board  Current Issue Archives Online Early Coming Soon Guidelines Subscriptions  e-Alerts    Login  
    Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
CORRESPONDENCE
Year : 2009  |  Volume : 54  |  Issue : 2  |  Page : 191-192
Olopatadine in chronic idiopathic urticaria


Shree Skin Centre, 22, L Market, Sector 8, Nerul, Navi Mumbai - 400 706, India

Date of Web Publication3-Jul-2009

Correspondence Address:
Kiran V Godse
Shree Skin Centre, 22, L Market, Sector 8, Nerul, Navi Mumbai - 400 706
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5154.53180

Rights and Permissions



How to cite this article:
Godse KV. Olopatadine in chronic idiopathic urticaria. Indian J Dermatol 2009;54:191-2

How to cite this URL:
Godse KV. Olopatadine in chronic idiopathic urticaria. Indian J Dermatol [serial online] 2009 [cited 2019 Aug 22];54:191-2. Available from: http://www.e-ijd.org/text.asp?2009/54/2/191/53180


Sir,

Olopatadine hydrochloride is one of the second-generation nonsedating antihistamines that is used for treating allergic disorders such as urticaria, rhinitis, and atopic dermatitis.[1] Olopatadine is a selective histamineH1-receptor antagonist possessing inhibitory effects on the release of inflammatory lipid mediators, such as leukotriene and thromboxane from human polymorphonuclear leukocytes and eosinophils. [2] Olopatadine was shown to be useful for the treatment of allergic rhinitis and chronic urticaria in double-blind clinical trials. Olopatadine was approved in Japan for the treatment of allergic rhinitis, chronic urticaria, eczema dermatitis, prurigo, pruritis cutaneous, psoriasis vulgaris, and erythema exsudativum multiforme in December 2000. [2]

Olopatadine hydrochloride was tested in patients with chronic idiopathic urticaria (CIU). CIU is defined by the almost daily presence of urticaria for at least six weeks without an identifiable cause. Aim of this study was to investigate the efficacy and side effects of olopatadine hydrochloride in CIU patients.

Twenty CIU patients in the age range of 14-70 years (11 men and 9 women, mean age: 41.95 years) were included in the study [Table 1]. Duration of urticaria ranged from 8-156 weeks (3 years) with average duration of 52 weeks (1 year) [Table 2]. History of NSAID allergy was present in two patients. Physical urticaria patients, pregnant women, and lactating mothers were not included in the study. All patients were investigated thoroughly with general and systemic examinations to rule out any septic focus or any obvious cause of urticaria, and their complete blood count, urine, and glucose levels were analyzed before initiating the therapy. Informed consents from all the study participants were obtained at their initial visit. All medications including antihistaminics were stopped a day prior to the study. The treatment comprised of T. olopatadine 5 mg orally twice a day after meals. The duration of therapy lasted either till the symptoms alleviated or up to one month. The clinical efficacy was measured using the urticaria activity score (UAS) at each follow-up. The follow-up evaluation was at 0, 2, and 4 weeks of therapy initiation. UAS is the sum of wheal number score and itch severity score. [3] The wheal numbers are graded from 0-3 as follows: 0 = <10 small wheals (diameter, <3 cm); 1 = 10-50 small wheals or <10 large wheals (diameter, >3 cm); 2 = >50 small wheals or 10-50 large wheals; and 3 = almost the whole body is covered. The severity of itching is graded from 0-3 (0, none; 1, mild; 2, moderate; and 3, severe).

Average UAS was 3.7 at 0 weeks which went down to 1.95 at the end of two weeks. At the end of four weeks, UAS further lessened to 1.2. Difference in UAS at 0 week and at 4 weeks was statistically significant (P <0.05). Two patients (10%) complained of headache and sedation after initiation of the therapy. Of eight patients (6 men and 2 women) with more than 36 weeks of urticaria, one patient did not respond to therapy and administration of steroid became necessary to control the condition. Olopatadine therapy was well tolerated without major side effects by most patients in this study.

Olopatadine, a newly developed histamine H1-receptor antagonist, was compared with cetirizine in its suppressive effects on histamine-induced wheal and flare reaction using an iontophoresis technique in a double-blind, cross-over, placebo-controlled study. As a result, olopatadine was found to have effects comparable to cetirizine. [4] In another study olopatadine and cetirizine showed the strongest and most persistent suppression of histamine-induced wheal and flare response. Also, olopatadine showed a considerable sedative effect with impaired psychomotor performance. [5]

Olopatadine is an effective treatment for CIU with sedation being a side effect in 10% of patients. Further studies in this direction with larger study groups are required to vindicate above findings.

 
   References Top

1.Morita K, Koga T, Moroi Y, Urabe K, Furue M. Rapid effects of olopatadine hydrochloride on the histamine-induced skin responses. J Dermatol 2002;29:709-12.  Back to cited text no. 1  [PUBMED]    
2.Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, et al . Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride: A new antiallergic drug. Jpn J Pharmacol 2002;88:379-97.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study. J Aller Clin Immunol 2002;110:484-8.  Back to cited text no. 3      
4.Morita E, Matsuo H, Zhang Y. Double-blind, crossover comparison of olopatadine and cetirizine versus placebo: Suppressive effects on skin response to histamine iontophoresis. J Dermatol 2005;32:58-61.  Back to cited text no. 4  [PUBMED]    
5.Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol 2004;29:526-32.  Back to cited text no. 5  [PUBMED]  [FULLTEXT]  



 
 
    Tables

  [Table 1], [Table 2]

This article has been cited by
1 Olopatadine versus levocetirizine in chronic urticaria: an observer-blind, randomized, controlled trial of effectiveness and safety
Amrita Sil,Santanu Kumar Tripathi,Anita Chaudhuri,Nilay Kanti Das,Avijit Hazra,Chiranjib Bagchi,Chowdhury Nazrul Islam
Journal of Dermatological Treatment. 2013; 24(6): 466
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Article in PDF (115 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    References
    Article Tables

 Article Access Statistics
    Viewed3110    
    Printed83    
    Emailed0    
    PDF Downloaded218    
    Comments [Add]    
    Cited by others 1    

Recommend this journal